All News Penumbra, Inc.

Equities

PEN

US70975L1070

Market Closed - Nyse Other stock markets 04:00:01 2024-05-08 pm EDT			5-day change	1st Jan Change
203.1 ^USD	-3.29%		-1.07%	-19.26%

May. 08	Morgan Stanley Cuts Price Target on Penumbra to $235 From $240, Keeps Equalweight Rating	MT
May. 07	Penumbra Q1 Non-GAAP EPS, Revenue Increase; Reaffirms 2024 Revenue Outlook	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Cuts Price Target on Penumbra to $235 From $240, Keeps Equalweight Rating	May. 08	MT
Penumbra Q1 Non-GAAP EPS, Revenue Increase; Reaffirms 2024 Revenue Outlook	May. 07	MT
Penumbra: Q1 Earnings Snapshot	May. 07	AQ
Transcript : Penumbra, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (PEN) PENUMBRA Reports Q1 Revenue $278.7M, vs. Street Est of $274.5M	May. 07	MT
Earnings Flash (PEN) PENUMBRA Reports Q1 EPS $0.41, vs. Street Est of $0.38	May. 07	MT
Penumbra, Inc. Reports First Quarter 2024 Financial Results	May. 07	PR
Penumbra, Inc. Reiterates Earnings Guidance for the Year 2024	May. 07	CI
Penumbra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference	May. 01	PR
Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	Apr. 23	PR
Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots	Apr. 23	CI
DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment	Apr. 17	MT
Penumbra, Inc. : The underdog in healthcare	Apr. 11
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024	Apr. 09	PR
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	Mar. 27	MT
Truist Securities Cuts Penumbra's Price Target to $280 From $290, Keeps Buy Rating	Mar. 22	MT
Piper Sandler Adjusts Price Target on Penumbra to $290 From $310, Maintains Overweight Rating	Feb. 26	MT
North American Morning Briefing : Traders Await -2-	Feb. 26	DJ
Deutsche Bank Raises Penumbra Price Target to $288 From $257, Maintains Buy Rating	Feb. 23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Penumbra, Inc. : The underdog in healthcare

April 11, 2024 at 09:39 pm EDT